{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:38:03Z","timestamp":1790818683170,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP160145"],"award-info":[{"award-number":["RP160145"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11912-019-0816-0","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T02:02:18Z","timestamp":1564106538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Novel Approaches to Ovarian Cancer Screening"],"prefix":"10.1007","volume":"21","author":[{"given":"Denise R.","family":"Nebgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert C.","family":"Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"issue":"4","key":"816_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396. \n                      https:\/\/doi.org\/10.3322\/caac.21456\n                      \n                    .","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"816_CR2","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra1813254","volume":"380","author":"P Morice","year":"2019","unstructured":"Morice P, Gouy S. Leary A. Mucinous ovarian carcinoma. N Engl J Med. 2019;380(13):1256\u201366. \n                      https:\/\/doi.org\/10.1056\/NEJMra1813254\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"816_CR3","unstructured":"Institute NC. Cancer stat facts: ovarian cancer. 2019. \n                      http:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html\n                      \n                    . Accessed 4\/6\/2019."},{"issue":"1","key":"816_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330. \n                      https:\/\/doi.org\/10.3322\/caac.21442\n                      \n                    .","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"816_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. \n                      https:\/\/doi.org\/10.3322\/caac.21492\n                      \n                    .","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"816_CR6","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386. \n                      https:\/\/doi.org\/10.1002\/ijc.29210\n                      \n                    .","journal-title":"Int J Cancer"},{"issue":"1","key":"816_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres LC, Cushing-Haugen KL, Kobel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019;111(1):60\u20138. \n                      https:\/\/doi.org\/10.1093\/jnci\/djy071\n                      \n                    .","journal-title":"J Natl Cancer Inst"},{"issue":"9972","key":"816_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","volume":"385","author":"C Allemani","year":"2015","unstructured":"Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet (London, England). 2015;385(9972):977\u20131010. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(14)62038-9\n                      \n                    .","journal-title":"Lancet (London, England)"},{"issue":"2","key":"816_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161\u20139. \n                      https:\/\/doi.org\/10.1097\/01.pas.0000213335.40358.47\n                      \n                    .","journal-title":"Am J Surg Pathol"},{"key":"816_CR10","doi-asserted-by":"publisher","first-page":"934261","DOI":"10.1155\/2014\/934261","volume":"2014","author":"M Koshiyama","year":"2014","unstructured":"Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014:934261. \n                      https:\/\/doi.org\/10.1155\/2014\/934261\n                      \n                    .","journal-title":"Biomed Res Int"},{"issue":"Suppl 10","key":"816_CR11","doi-asserted-by":"publisher","first-page":"x16","DOI":"10.1093\/annonc\/mdt463.","volume":"24","author":"RJ Kurman","year":"2013","unstructured":"Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24(Suppl 10):x16\u201321. \n                      https:\/\/doi.org\/10.1093\/annonc\/mdt463.","journal-title":"Ann Oncol"},{"issue":"4","key":"816_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011.","volume":"186","author":"RJ Kurman","year":"2016","unstructured":"Kurman RJ, Shih Ie M. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733\u201347. \n                      https:\/\/doi.org\/10.1016\/j.ajpath.2015.11.011.","journal-title":"Am J Pathol"},{"issue":"4","key":"816_CR13","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1210\/en.2011-2123","volume":"153","author":"I Romero","year":"2012","unstructured":"Romero I, Bast RC Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153(4):1593\u2013602. \n                      https:\/\/doi.org\/10.1210\/en.2011-2123\n                      \n                    .","journal-title":"Endocrinology"},{"issue":"1","key":"816_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","volume":"19","author":"CP Crum","year":"2007","unstructured":"Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):3\u20139. \n                      https:\/\/doi.org\/10.1097\/GCO.0b013e328011a21f\n                      \n                    .","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"2","key":"816_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","volume":"30","author":"F Medeiros","year":"2006","unstructured":"Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30(2):230\u20136.","journal-title":"Am J Surg Pathol"},{"key":"816_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ctrv.2018.06.004","volume":"69","author":"AA Gockley","year":"2018","unstructured":"Gockley AA, Elias KM. Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction. Cancer Treat Rev. 2018;69:66\u201371. \n                      https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.004\n                      \n                    .","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"816_CR17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(11):1329\u201333. \n                      https:\/\/doi.org\/10.1200\/JCO.2006.09.1066\n                      \n                    .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"816_CR18","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology. Genetic\/familial high-risk assessment: breast and ovarian (version 3.2019). 2019. \n                      https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf\n                      \n                    . Accessed 4\/7\/2019."},{"issue":"1","key":"816_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","volume":"150","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2018;150(1):85\u201391. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.011\n                      \n                    .","journal-title":"Gynecol Oncol"},{"issue":"3","key":"816_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/gutjnl-2015-309675","volume":"66","author":"P Moller","year":"2017","unstructured":"Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66(3):464\u201372. \n                      https:\/\/doi.org\/10.1136\/gutjnl-2015-309675\n                      \n                    .","journal-title":"Gut"},{"key":"816_CR21","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology. Genetic\/familial high-risk assessment: colorectal (version 1.2018). 2018. \n                      https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf\n                      \n                    . Accessed 4\/7\/2019."},{"issue":"5","key":"816_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/ng.2224","volume":"44","author":"C Loveday","year":"2012","unstructured":"Loveday C, Turnbull C, Ruark E, Xicola RM, Ramsay E, Hughes D, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet. 2012;44(5):475\u20136; author reply 6. \n                      https:\/\/doi.org\/10.1038\/ng.2224\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"4","key":"816_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482\u201390. \n                      https:\/\/doi.org\/10.1001\/jamaoncol.2015.5495\n                      \n                    .","journal-title":"JAMA Oncol"},{"issue":"26","key":"816_CR24","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/jco.2015.61.2408","volume":"33","author":"H Song","year":"2015","unstructured":"Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(26):2901\u20137. \n                      https:\/\/doi.org\/10.1200\/jco.2015.61.2408\n                      \n                    .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"816_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/ng.893","volume":"43","author":"C Loveday","year":"2011","unstructured":"Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879\u201382. \n                      https:\/\/doi.org\/10.1038\/ng.893\n                      \n                    .","journal-title":"Nat Genet"},{"key":"816_CR26","doi-asserted-by":"publisher","unstructured":"Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst. 2015;107(11). \n                      https:\/\/doi.org\/10.1093\/jnci\/djv214\n                      \n                    .","DOI":"10.1093\/jnci\/djv214"},{"issue":"6","key":"816_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3961\/jpmph.16.066","volume":"49","author":"HK Sung","year":"2016","unstructured":"Sung HK, Ma SH, Choi J-Y, Hwang Y, Ahn C, Kim B-G, et al. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: a systematic review and meta-analysis. J Prev Med Public Health. 2016;49(6):349\u201366. \n                      https:\/\/doi.org\/10.3961\/jpmph.16.066\n                      \n                    .","journal-title":"J Prev Med Public Health"},{"key":"816_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","volume":"122","author":"LJ Havrilesky","year":"2013","unstructured":"Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systemic review and meta-analysis. Obstet Gynecol. 2013;122:139\u201347.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"816_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/humupd\/dmq030","volume":"17","author":"D Cibula","year":"2011","unstructured":"Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update. 2011;17(1):55\u201367. \n                      https:\/\/doi.org\/10.1093\/humupd\/dmq030\n                      \n                    .","journal-title":"Hum Reprod Update"},{"issue":"1","key":"816_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","volume":"4","author":"I Jacobs","year":"1989","unstructured":"\u2022 Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod (Oxford, England). 1989;4(1):1\u201312. Established the specificity of 99.6% and PPV of 10% for OC screening test.","journal-title":"Hum Reprod (Oxford, England)"},{"issue":"3","key":"816_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2217\/17520363.2.3.291","volume":"2","author":"PM Das","year":"2008","unstructured":"Das PM, Bast RC Jr. Early detection of ovarian cancer. Biomark Med. 2008;2(3):291\u2013303. \n                      https:\/\/doi.org\/10.2217\/17520363.2.3.291\n                      \n                    .","journal-title":"Biomark Med"},{"issue":"6","key":"816_CR32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.hoc.2018.07.003","volume":"32","author":"KM Elias","year":"2018","unstructured":"Elias KM, Guo J, Bast RC Jr. Early detection of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):903\u201314. \n                      https:\/\/doi.org\/10.1016\/j.hoc.2018.07.003\n                      \n                    .","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10 Suppl","key":"816_CR33","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G","volume":"76","author":"SJ Skates","year":"1995","unstructured":"Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(10 Suppl):2004\u201310.","journal-title":"Cancer."},{"issue":"6","key":"816_CR34","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/AOG.0b013e318238d030","volume":"118","author":"JR van Nagell Jr","year":"2011","unstructured":"van Nagell JR Jr, Miller RW, DeSimone CP, Ueland FR, Podzielinski I, Goodrich ST, et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol. 2011;118(6):1212\u201321. \n                      https:\/\/doi.org\/10.1097\/AOG.0b013e318238d030\n                      \n                    .","journal-title":"Obstet Gynecol"},{"issue":"3","key":"816_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","volume":"18","author":"H Kobayashi","year":"2008","unstructured":"Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer. 2008;18(3):414\u201320. \n                      https:\/\/doi.org\/10.1111\/j.1525-1438.2007.01035.x\n                      \n                    .","journal-title":"Int J Gynecol Cancer"},{"issue":"22","key":"816_CR36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295\u2013303. \n                      https:\/\/doi.org\/10.1001\/jama.2011.766\n                      \n                    .","journal-title":"JAMA"},{"issue":"2","key":"816_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ygyno.2016.08.334","volume":"143","author":"PF Pinsky","year":"2016","unstructured":"Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol. 2016;143(2):270\u20135. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.334\n                      \n                    .","journal-title":"Gynecol Oncol"},{"issue":"10022","key":"816_CR38","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/s0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"\u2022 Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet (London, England). 2016;387(10022):945\u201356. \n                      https:\/\/doi.org\/10.1016\/s0140-6736(15)01224-6\n                      \n                    . UKCTOCS trial demonstrated a possible mortality reduction.","journal-title":"Lancet (London, England)"},{"issue":"9","key":"816_CR39","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/1471-0528.12870","volume":"121","author":"J Barrett","year":"2014","unstructured":"Barrett J, Jenkins V, Farewell V, Menon U, Jacobs I, Kilkerr J, et al. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). BJOG. 2014;121(9):1071\u20139. \n                      https:\/\/doi.org\/10.1111\/1471-0528.12870\n                      \n                    .","journal-title":"BJOG"},{"issue":"18","key":"816_CR40","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1200\/jco.2014.59.4945","volume":"33","author":"U Menon","year":"2015","unstructured":"Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(18):2062\u201371. \n                      https:\/\/doi.org\/10.1200\/jco.2014.59.4945\n                      \n                    .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"816_CR41","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1002\/cncr.28183","volume":"119","author":"KH Lu","year":"2013","unstructured":"Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119(19):3454\u201361. \n                      https:\/\/doi.org\/10.1002\/cncr.28183\n                      \n                    .","journal-title":"Cancer"},{"issue":"5","key":"816_CR42","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1172\/JCI110380","volume":"68","author":"RC Bast Jr","year":"1981","unstructured":"Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331\u20137.","journal-title":"J Clin Invest"},{"issue":"15","key":"816_CR43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/nejm198310133091503","volume":"309","author":"RC Bast Jr","year":"1983","unstructured":"Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883\u20137. \n                      https:\/\/doi.org\/10.1056\/nejm198310133091503\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"29","key":"816_CR44","doi-asserted-by":"publisher","first-page":"27371","DOI":"10.1074\/jbc.M103554200","volume":"276","author":"BW Yin","year":"2001","unstructured":"Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276(29):27371\u20135. \n                      https:\/\/doi.org\/10.1074\/jbc.M103554200\n                      \n                    .","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"816_CR45","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/IGC.0b013e318256488a","volume":"22","author":"SJ Skates","year":"2012","unstructured":"Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer. 2012;22(Suppl 1):S24\u2013S6. \n                      https:\/\/doi.org\/10.1097\/IGC.0b013e318256488a\n                      \n                    .","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"816_CR46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/jama.2017.21421","volume":"319","author":"JT Henderson","year":"2018","unstructured":"Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. Jama. 2018;319(6):595\u2013606. \n                      https:\/\/doi.org\/10.1001\/jama.2017.21421\n                      \n                    .","journal-title":"Jama"},{"issue":"2","key":"816_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80\u20137. \n                      https:\/\/doi.org\/10.1093\/jnci\/djn442\n                      \n                    .","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"816_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ygyno.2017.02.008","volume":"145","author":"PL Mai","year":"2017","unstructured":"Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, et al. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: an NRG Oncology\/Gynecologic Oncology Group study. Gynecol Oncol. 2017;145(1):122\u20139. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.008\n                      \n                    .","journal-title":"Gynecol Oncol"},{"issue":"13","key":"816_CR49","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1200\/jco.2016.69.9330","volume":"35","author":"AN Rosenthal","year":"2017","unstructured":"\u2022 Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(13):1411\u201320. \n                      https:\/\/doi.org\/10.1200\/jco.2016.69.9330\n                      \n                    . Demonstrates a stage shift from screening for patients at high risk.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"816_CR50","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/1055-9965.epi-07-2703.","volume":"17","author":"MH Greene","year":"2008","unstructured":"Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008;17(3):594\u2013604. \n                      https:\/\/doi.org\/10.1158\/1055-9965.epi-07-2703.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"14","key":"816_CR51","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1158\/1078-0432.ccr-15-2750","volume":"23","author":"SJ Skates","year":"2017","unstructured":"\u2022 Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, et al. Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk - combined results from two screening trials. Clin Cancer Res. 2017;23(14):3628\u201337. \n                      https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-2750\n                      \n                    . Additional experience using two-stage screening for women at high risk of ovarian cancer.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"816_CR52","first-page":"3695","volume":"63","author":"I Hellstrom","year":"2003","unstructured":"Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695\u2013700.","journal-title":"Cancer Res"},{"issue":"2","key":"816_CR53","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402\u20138. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2007.10.017\n                      \n                    .","journal-title":"Gynecol Oncol"},{"issue":"3","key":"816_CR54","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/1940-6207.capr-10-0195","volume":"4","author":"DW Cramer","year":"2011","unstructured":"Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011;4(3):365\u201374. \n                      https:\/\/doi.org\/10.1158\/1940-6207.capr-10-0195\n                      \n                    .","journal-title":"Cancer Prev Res (Phila)"},{"issue":"18","key":"816_CR55","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1158\/1078-0432.ccr-16-0316.","volume":"22","author":"KL Terry","year":"2016","unstructured":"Terry KL, Schock H, Fortner RT, Husing A, Fichorova RN, Yamamoto HS, et al. A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. Clin Cancer Res. 2016;22(18):4664\u201375. \n                      https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-0316.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"816_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/1940-6207.CAPR-18-0377","volume":"12","author":"Archana R. Simmons","year":"2019","unstructured":"Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, et al. Complementary longitudinal serum biomarkers to CA125 for early detection of ovarian cancer. Cancer Prev Res (Phila). 2019. \n                      https:\/\/doi.org\/10.1158\/1940-6207.capr-18-0377\n                      \n                    .","journal-title":"Cancer Prevention Research"},{"issue":"3","key":"816_CR57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.trecan.2017.02.003","volume":"3","author":"IK Macdonald","year":"2017","unstructured":"Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: opportunities for early cancer detection. Trends Cancer. 2017;3(3):198\u2013213. \n                      https:\/\/doi.org\/10.1016\/j.trecan.2017.02.003\n                      \n                    .","journal-title":"Trends Cancer"},{"issue":"1","key":"816_CR58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49\u201356. \n                      https:\/\/doi.org\/10.1002\/path.2696\n                      \n                    .","journal-title":"J Pathol"},{"issue":"19","key":"816_CR59","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1158\/1078-0432.ccr-17-0284","volume":"23","author":"WL Yang","year":"2017","unstructured":"\u2022 Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, et al. Elevation of TP53 autoantibody before CA125 in preclinical invasive epithelial ovarian cancer. Clin Cancer Res. 2017;23(19):5912\u201322. \n                      https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-0284\n                      \n                    . Anti-TP53 autoantibodies produce lead time over CA125.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"816_CR60","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ygyno.2017.07.138","volume":"147","author":"RT Fortner","year":"2017","unstructured":"Fortner RT, Damms-Machado A, Kaaks R. Systematic review: tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol. 2017;147(2):465\u201380. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.138\n                      \n                    .","journal-title":"Gynecol Oncol"},{"issue":"2","key":"816_CR61","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ygyno.2005.12.011","volume":"102","author":"AE Lokshin","year":"2006","unstructured":"Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol. 2006;102(2):244\u201351. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2005.12.011\n                      \n                    .","journal-title":"Gynecol Oncol"},{"issue":"1","key":"816_CR62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-016-0536-0","volume":"15","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15(1):48. \n                      https:\/\/doi.org\/10.1186\/s12943-016-0536-0\n                      \n                    .","journal-title":"Mol Cancer"},{"issue":"5","key":"816_CR63","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3892\/ijo.2017.3948","volume":"50","author":"C Palma Flores","year":"2017","unstructured":"Palma Flores C, Garcia-Vazquez R, Gallardo Rincon D, Ruiz-Garcia E, Astudillo de la Vega H, Marchat LA, et al. MicroRNAs driving invasion and metastasis in ovarian cancer: opportunities for translational medicine (review). Int J Oncol. 2017;50(5):1461\u201376. \n                      https:\/\/doi.org\/10.3892\/ijo.2017.3948\n                      \n                    .","journal-title":"Int J Oncol"},{"issue":"2","key":"816_CR64","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.bbcan.2010.07.002","volume":"1806","author":"J Wittmann","year":"2010","unstructured":"Wittmann J, Jack HM. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta. 2010;1806(2):200\u20137. \n                      https:\/\/doi.org\/10.1016\/j.bbcan.2010.07.002\n                      \n                    .","journal-title":"Biochim Biophys Acta"},{"key":"816_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-627","volume":"12","author":"CW Kan","year":"2012","unstructured":"Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, Marsh DJ, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer. 2012;12:627. \n                      https:\/\/doi.org\/10.1186\/1471-2407-12-627\n                      \n                    .","journal-title":"BMC Cancer"},{"issue":"11","key":"816_CR66","doi-asserted-by":"publisher","first-page":"e77853","DOI":"10.1371\/journal.pone.0077853","volume":"8","author":"H Zheng","year":"2013","unstructured":"Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 2013;8(11):e77853. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0077853\n                      \n                    .","journal-title":"PLoS One"},{"issue":"52","key":"816_CR67","doi-asserted-by":"publisher","first-page":"89811","DOI":"10.18632\/oncotarget.20688","volume":"8","author":"A Yokoi","year":"2017","unstructured":"Yokoi A, Yoshioka Y, Hirakawa A, Yamamoto Y, Ishikawa M, Ikeda SI, et al. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017;8(52):89811\u201323. \n                      https:\/\/doi.org\/10.18632\/oncotarget.20688\n                      \n                    .","journal-title":"Oncotarget."},{"key":"816_CR68","doi-asserted-by":"publisher","unstructured":"\u2022 Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, et al. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. eLife. 2017;6. \n                      https:\/\/doi.org\/10.7554\/eLife.28932\n                      \n                    . miRNA has potential for early detection of ovarian cancer.","DOI":"10.7554\/eLife.28932"},{"issue":"15","key":"816_CR69","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.clinbiochem.2015.04.005","volume":"48","author":"KM Patel","year":"2015","unstructured":"Patel KM, Tsui DWY. The translational potential of circulating tumour DNA in oncology. Clin Biochem. 2015;48(15):957\u201361. \n                      https:\/\/doi.org\/10.1016\/j.clinbiochem.2015.04.005\n                      \n                    .","journal-title":"Clin Biochem"},{"issue":"1","key":"816_CR70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13048-017-0369-5","volume":"10","author":"X Cheng","year":"2017","unstructured":"Cheng X, Zhang L, Chen Y, Qing C. Circulating cell-free DNA and circulating tumor cells, the \u201cliquid biopsies\u201d in ovarian cancer. J Ovarian Res. 2017;10(1):75. \n                      https:\/\/doi.org\/10.1186\/s13048-017-0369-5\n                      \n                    .","journal-title":"J Ovarian Res"},{"issue":"224","key":"816_CR71","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"\u2022 Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. \n                      https:\/\/doi.org\/10.1126\/scitranslmed.3007094\n                      \n                    . Use of ctDNA for the detection of human cancers.","journal-title":"Sci Transl Med"},{"issue":"36","key":"816_CR72","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2015.61.3083","volume":"33","author":"E Maritschnegg","year":"2015","unstructured":"Maritschnegg E, Wang Y, Pecha N, Horvat R, Van Nieuwenhuysen E, Vergote I, et al. Lavage of the uterine cavity for molecular detection of M\u00fcllerian duct carcinomas: a proof-of-concept study. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(36):4293\u2013300. \n                      https:\/\/doi.org\/10.1200\/JCO.2015.61.3083\n                      \n                    .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6378","key":"816_CR73","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"\u2022 Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science (New York, NY). 2018;359(6378):926\u201330. \n                      https:\/\/doi.org\/10.1126\/science.aar3247\n                      \n                    . Protein biomarkers and ctDNA were used to detect multiple cancers.","journal-title":"Science (New York, NY)"},{"issue":"7","key":"816_CR74","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","volume":"92","author":"M Esteller","year":"2000","unstructured":"Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"816_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11620","volume":"7","author":"TE Bartlett","year":"2016","unstructured":"Bartlett TE, Chindera K, McDermott J, Breeze CE, Cooke WR, Jones A, et al. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. Nat Commun. 2016;7:11620. \n                      https:\/\/doi.org\/10.1038\/ncomms11620\n                      \n                    .","journal-title":"Nat Commun"},{"issue":"1","key":"816_CR76","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13073-017-0500-7","volume":"9","author":"M Widschwendter","year":"2017","unstructured":"Widschwendter M, Zikan M, Wahl B, Lempiainen H, Paprotka T, Evans I, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. 2017;9(1):116. \n                      https:\/\/doi.org\/10.1186\/s13073-017-0500-7\n                      \n                    .","journal-title":"Genome Med"},{"issue":"1","key":"816_CR77","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ygyno.2013.04.048","volume":"130","author":"Q Zhang","year":"2013","unstructured":"Zhang Q, Hu G, Yang Q, Dong R, Xie X, Ma D, et al. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 2013;130(1):132\u20139. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.048\n                      \n                    .","journal-title":"Gynecol Oncol"},{"issue":"3","key":"816_CR78","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/uog.17557","volume":"51","author":"KB Mathieu","year":"2018","unstructured":"\u2022 Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC Jr. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol. 2018;51(3):293\u2013303. \n                      https:\/\/doi.org\/10.1002\/uog.17557\n                      \n                    . Up to date review of imaging for early detection of ovarian cancer.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"7","key":"816_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000114","volume":"6","author":"POPC Brown","year":"2009","unstructured":"Brown POPC. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009;6(7):e1000114.","journal-title":"PLoS Med"},{"issue":"8","key":"816_CR80","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1371\/journal.pmed.0050170","volume":"5","author":"AM Lutz","year":"2008","unstructured":"Lutz AM, Willmann JK, Cochran FV, Ray P, Gambhir SS. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med. 2008;5(8):e170. \n                      https:\/\/doi.org\/10.1371\/journal.pmed.0050170\n                      \n                    .","journal-title":"PLoS Med"},{"issue":"3","key":"816_CR81","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/cmmi.499","volume":"7","author":"NL Adolphi","year":"2012","unstructured":"Adolphi NL, Butler KS, Lovato DM, Tessier TE, Trujillo JE, Hathaway HJ, et al. Imaging of Her2-targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID-detected magnetic relaxometry and MRI. Contrast Media Mol Imaging. 2012;7(3):308\u201319. \n                      https:\/\/doi.org\/10.1002\/cmmi.499\n                      \n                    .","journal-title":"Contrast Media Mol Imaging"},{"issue":"21","key":"816_CR82","doi-asserted-by":"publisher","first-page":"8310","DOI":"10.1158\/0008-5472.CAN-09-1083","volume":"69","author":"JE Jaetao","year":"2009","unstructured":"Jaetao JE, Butler KS, Adolphi NL, Lovato DM, Bryant HC, Rabinowitz I, et al. Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles. Cancer Res. 2009;69(21):8310\u20136. \n                      https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1083\n                      \n                    .","journal-title":"Cancer Res"},{"issue":"4","key":"816_CR83","doi-asserted-by":"publisher","first-page":"eaaq1090","DOI":"10.1126\/sciadv.aaq1090","volume":"4","author":"RM Williams","year":"2018","unstructured":"Williams RM, Lee C, Galassi TV, Harvey JD, Leicher R, Sirenko M, et al. Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant. Sci Adv. 2018;4(4):eaaq1090. \n                      https:\/\/doi.org\/10.1126\/sciadv.aaq1090\n                      \n                    .","journal-title":"Sci Adv"},{"issue":"7","key":"816_CR84","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/IGC.0b013e3181a386e5","volume":"19","author":"LR Medeiros","year":"2009","unstructured":"Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of ultrasonography with color Doppler in ovarian tumor: a systematic quantitative review. Int J Gynecol Cancer. 2009;19(7):1214\u201320. \n                      https:\/\/doi.org\/10.1111\/IGC.0b013e3181a386e5\n                      \n                    .","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"816_CR85","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2214\/ajr.09.3446","volume":"194","author":"AC Fleischer","year":"2010","unstructured":"Fleischer AC, Lyshchik A, Andreotti RF, Hwang M, Jones HW 3rd, Fishman DA. Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles. AJR Am J Roentgenol. 2010;194(2):343\u20138. \n                      https:\/\/doi.org\/10.2214\/ajr.09.3446\n                      \n                    .","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"816_CR86","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ultrasmedbio.2012.11.008","volume":"39","author":"H Xiang","year":"2013","unstructured":"Xiang H, Huang R, Cheng J, Gulinaer S, Hu R, Feng Y, et al. Value of three-dimensional contrast-enhanced ultrasound in the diagnosis of small adnexal masses. Ultrasound Med Biol. 2013;39(5):761\u20138. \n                      https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2012.11.008\n                      \n                    .","journal-title":"Ultrasound Med Biol"},{"issue":"3","key":"816_CR87","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ygyno.2010.12.333","volume":"120","author":"JN McAlpine","year":"2011","unstructured":"McAlpine JN, El Hallani S, Lam SF, Kalloger SE, Luk M, Huntsman DG, et al. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol Oncol. 2011;120(3):385\u201392. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2010.12.333\n                      \n                    .","journal-title":"Gynecol Oncol"},{"issue":"7","key":"816_CR88","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/humrep\/13.7.1815","volume":"13","author":"H Dechaud","year":"1998","unstructured":"Dechaud H, Daures JP, Hedon B. Prospective evaluation of falloposcopy. Human Reprod (Oxford, England). 1998;13(7):1815\u20138.","journal-title":"Human Reprod (Oxford, England)"},{"issue":"5","key":"816_CR89","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jmig.2014.03.017","volume":"21","author":"D Lum","year":"2014","unstructured":"Lum D, Guido R, Rodriguez E, Lee T, Mansuria S, D\u2019Ambrosio L, et al. Brush cytology of the fallopian tube and implications in ovarian cancer screening. J Minim Invasive Gynecol. 2014;21(5):851\u20136. \n                      https:\/\/doi.org\/10.1016\/j.jmig.2014.03.017\n                      \n                    .","journal-title":"J Minim Invasive Gynecol"},{"issue":"2","key":"816_CR90","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3892\/ol.2016.5493","volume":"13","author":"S Gizzo","year":"2017","unstructured":"Gizzo S, Noventa M, Quaranta M, Vitagliano A, Saccardi C, Litta P, et al. A novel hysteroscopic approach for ovarian cancer screening\/early diagnosis. Oncol Lett. 2017;13(2):549\u201353. \n                      https:\/\/doi.org\/10.3892\/ol.2016.5493\n                      \n                    .","journal-title":"Oncol Lett"},{"issue":"1","key":"816_CR91","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12935-016-0354-x","volume":"16","author":"H Chen","year":"2016","unstructured":"Chen H, Klein R, Arnold S, Chambers S, Zheng W. Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy. Cancer Cell Int. 2016;16(1):78. \n                      https:\/\/doi.org\/10.1186\/s12935-016-0354-x\n                      \n                    .","journal-title":"Cancer Cell Int"},{"key":"816_CR92","doi-asserted-by":"publisher","unstructured":"Chen H, Klein R, Arnold S, Wang Y, Chambers S, Zheng W. Tubal cytology of the fallopian tube as a promising tool for ovarian cancer early detection. J Vis Exp. 2017;125. \n                      https:\/\/doi.org\/10.3791\/55887\n                      \n                    .","DOI":"10.3791\/55887"},{"issue":"3","key":"816_CR93","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/bjc.2013.402","volume":"109","author":"I Otsuka","year":"2013","unstructured":"Otsuka I, Kameda S, Hoshi K. Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity. Br J Cancer. 2013;109(3):603\u20139. \n                      https:\/\/doi.org\/10.1038\/bjc.2013.402\n                      \n                    .","journal-title":"Br J Cancer"},{"issue":"6","key":"816_CR94","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1159\/000353825","volume":"57","author":"EF Rodriguez","year":"2013","unstructured":"Rodriguez EF, Lum D, Guido R, Austin RM. Cytologic findings in experimental in vivo fallopian tube brush specimens. Acta Cytol. 2013;57(6):611\u20138. \n                      https:\/\/doi.org\/10.1159\/000353825\n                      \n                    .","journal-title":"Acta Cytol"},{"issue":"167","key":"816_CR95","doi-asserted-by":"publisher","first-page":"167ra4","DOI":"10.1126\/scitranslmed.3004952","volume":"5","author":"I Kinde","year":"2013","unstructured":"Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih Ie M, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167ra4. \n                      https:\/\/doi.org\/10.1126\/scitranslmed.3004952\n                      \n                    .","journal-title":"Sci Transl Med"},{"issue":"433","key":"816_CR96","doi-asserted-by":"publisher","first-page":"eaap8793","DOI":"10.1126\/scitranslmed.aap8793","volume":"10","author":"Y Wang","year":"2018","unstructured":"Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018;10(433):eaap8793. \n                      https:\/\/doi.org\/10.1126\/scitranslmed.aap8793\n                      \n                    .","journal-title":"Sci Transl Med"},{"key":"816_CR97","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/cncr.32004","volume":"125","author":"RC Bast Jr","year":"2019","unstructured":"Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, et al. Critical questions in ovarian cancer research and treatment: report of an American Association for Cancer Research Special Conference. Cancer. 2019;125:1963\u201372. \n                      https:\/\/doi.org\/10.1002\/cncr.32004\n                      \n                    .","journal-title":"Cancer."},{"key":"816_CR98","doi-asserted-by":"publisher","first-page":"124","DOI":"10.14694\/EDBK_180330","volume":"37","author":"Marian J. Mourits","year":"2017","unstructured":"Mourits MJ, de Bock GH. European\/US comparison and contrasts in ovarian cancer screening and prevention in a high-risk population. ASCO Educ Book. 2017;2017:124\u20137.","journal-title":"American Society of Clinical Oncology Educational Book"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-019-0816-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T23:40:23Z","timestamp":1595634023000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-019-0816-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":98,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1007\/s11912-019-0816-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,26]]},"assertion":[{"value":"26 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Denise R. Nebgen declares that she has no conflict of interest.Karen H. Lu declares that she has no conflict of interest.Robert C. Bast Jr. receives royalties from Fujirebio Diagnostics, Inc., for the discovery of CA125.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"75"}}